Live Feeds
● LIVE Updated 17m ago · 12 sources tracked

Ultragenyx Reports Third Quarter 2026 Financial Results, Announces Substantial Expense Reductions, and Reaffirms Profitability in 2027—Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical reported third-quarter 2026 total revenue of $173 million, including $109 million from CRYSVITA and $30 million from DOJOLVI. Alongside its financial results, the company announced major structural changes, including a 20% workforce reduction and the elimination of assets like a Wilson disease gene therapy to slash research and development spending. Management reaffirmed its financial targets, aiming for profitability in 2027 and maintaining full-year 2026 revenue guidance between $730 million and $760 million. The restructuring is expected to cut 2027 research and development expenses by at least 50% compared to 2025 levels.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~3 min
Speed:
RSS Source map (12)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ Ultragenyx reported third quarter 2026 total revenue of $173 million, which includes $109 million from CRYSVITA and $30 million from DOJOLVI.
  • ✓ The company announced plans to lay off 20% of its employees and scrap a Wilson disease gene therapy.
  • ✓ Ultragenyx reaffirmed its profitability target for 2027 and its 2026 revenue guidance of $730 million to $760 million.
  • ✓ The Food and Drug Administration approved BLAs for GENGLYCOS and FAYUVI in the third quarter of 2026.
🛡️ Source Corroboration: 12 independent reporting domains (100% confidence) ⏱ Read time: ~2 min

What changed

Ultragenyx reported third-quarter 2026 earnings alongside a sweeping restructuring plan to halve research and development expenses and lay off 20% of its staff.

Live updates

  1. Ultragenyx Cuts 20% of Workforce and Reaffirms 2027 Profitability

    Ultragenyx Pharmaceutical reported third-quarter 2026 total revenue of $173 million, including $109 million from CRYSVITA and $30 million from DOJOLVI. Alongside its financial results, the company announced major structural changes, including a 20% workforce reduction and the elimination of assets like a Wilson disease gene therapy to slash research and development spending. Management reaffirmed its financial targets, aiming for profitability in 2027 and maintaining full-year 2026 revenue guidance between $730 million and $760 million. The restructuring is expected to cut 2027 research and development expenses by at least 50% compared to 2025 levels.

    Why it matters

    The biotechnology firm is aggressively trimming its pipeline and operational footprint to reach financial self-sufficiency. These measures include leveraging non-dilutive proceeds, such as an agreement for two priority review vouchers generating a combined sales price of $413 million. The strategic pivot follows recent regulatory milestones, including Food and Drug Administration approvals for GENGLYCOS and FAYUVI during the third quarter.

    What is confirmed

    • Ultragenyx reported third quarter 2026 total revenue of $173 million, which includes $109 million from CRYSVITA and $30 million from DOJOLVI.
    • The company announced plans to lay off 20% of its employees and scrap a Wilson disease gene therapy.
    • Ultragenyx reaffirmed its profitability target for 2027 and its 2026 revenue guidance of $730 million to $760 million.
    • The Food and Drug Administration approved BLAs for GENGLYCOS and FAYUVI in the third quarter of 2026.
    • Ultragenyx entered an agreement for two Priority Review Vouchers with a combined sales price of $413 million.

    What to watch next

    • Execution of the planned 20% workforce reduction and asset eliminations
    • Realization of the projected 50% reduction in 2027 R&D expenses compared to 2025
    • Progress toward achieving profitability in 2027
    Sources used for this update (15)
    1. www.nbcnews.com — Tracking the 2026 early vote
    2. www.foxnews.com — Florida 2026 Midterm Election Results
    3. Ultragenyx — Ultragenyx Reports Third Quarter 2026 Financial Results, Announces Substantial Expense Reductions, and Reaffirms Profitability in 2027—Ultragenyx Pharmaceutical Inc.
    4. Fierce Biotech — Ultragenyx shrinks workforce and axes assets to halve R&D spend
    5. Endpoints News — Ultragenyx to lay off 20% of employees, scrap a Wilson disease gene therapy
    6. MarketBeat — Ultragenyx Pharmaceutical (NASDAQ:RARE) Issues Quarterly Earnings Results
    7. TradingView — Key facts: FDA wins; Ultragenyx exits studies, targets 2027 profit
    8. www.foxnews.com — 2026 Senate Election Results | Fox News Midterm Senate Elections
    9. www.biospace.com — Ultragenyx Reports Third Quarter 2026 Financial Results ...
    10. finance.yahoo.com — Ultragenyx Reports Third Quarter 2026 Financial Results ...
    11. markets.businessinsider.com — Ultragenyx Reports Third Quarter 2026 Financial Results ...
    12. finance.yahoo.com — TG Therapeutics Reports Third Quarter 2026 Financial Results and Raises Full-Year Revenue Guidance
    confidence 100%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community